-
公开(公告)号：US10800826B2
公开(公告)日：2020-10-13
申请号：US15765505
申请日：2016-10-04
发明人： Paul Carrington , Grigori Ermakov , Robert M. Garbaccio , Wolfgang Seghezzi , Elisabetta Bianchi , Federica Orvieto , Dennis Gately , Nick Knudsen , Anthony Manibusan
摘要： Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
-
公开(公告)号：US10550190B2
公开(公告)日：2020-02-04
申请号：US15301564
申请日：2015-03-30
发明人： Robert M. Garbaccio , Jeffrey Kern , Philip E. Brandish , Sanjiv Shah , Linda Liang , Ying Sun , Jianing Wang , Nick Knudsen , Andrew Beck , Anthony Manibusan , Dennis Gately
摘要： Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).
-
公开(公告)号：US20170182181A1
公开(公告)日：2017-06-29
申请号：US15301564
申请日：2015-03-30
发明人： Robert M. Garbaccio , Jeffrey Kern , Philip E. Brandish , Sanjiv Shah , Linda Liang , Ying Sun , Jianing Wang , Nick Knudsen , Andrew Beck , Anthony Manibusan , Dennis Gately
CPC分类号： C07K16/2866 , A61K47/6803 , A61K47/6817 , A61K47/6849 , A61K47/6889 , A61K51/1045 , C07F9/091 , C07F9/098 , C07F9/12 , C07F9/2458 , C07F9/572 , C07F9/65517 , C07F9/65583 , C07F9/65586 , C07F9/6561 , C07H19/10
摘要： Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).
-
公开(公告)号：US11510993B2
公开(公告)日：2022-11-29
申请号：US15765515
申请日：2016-09-30
发明人： Philip E. Brandish , Robert M. Garbaccio , Jeffrey Kern , Linda Liang , Sanjiv Shah , Dennis Zaller , Andrew Beck , Dennis Gately , Nick Knudsen , Anthony Manibusan , Jianing Wang , Ying Sun
摘要： Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.
-
公开(公告)号：US11554172B2
公开(公告)日：2023-01-17
申请号：US17031249
申请日：2020-09-24
摘要： Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
-
6.发明申请公开(公告)号：US20190071483A1
公开(公告)日：2019-03-07
申请号：US15765505
申请日：2016-10-04
发明人： Paul Carrington , Grigori Ermakov , Robert M. Garbaccio , Wolfgang Seghezzi , Elisabetta Bianchi , Federica Orvieto , Dennis Gately , Nick Knudsen , Anthony Manibusan
IPC分类号： C07K14/605 , A61K47/68 , C07K16/26 , C07K16/28 , A61P3/10
CPC分类号： C07K14/605 , A61K47/6811 , A61K47/6843 , A61K2039/505 , A61P3/10 , C07K16/26 , C07K16/2869 , C07K2317/75 , C07K2319/00
摘要： Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
-
公开(公告)号：US20210015930A1
公开(公告)日：2021-01-21
申请号：US17031249
申请日：2020-09-24
摘要： Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
-
公开(公告)号：US20190030171A1
公开(公告)日：2019-01-31
申请号：US16072347
申请日：2017-01-24
申请人： Robert M. Garbaccio , Jeffrey C. Kern , James J. Mulhearn , Philip E. Brandish , Merck Sharp & Dohme Corp.
摘要： Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
-
公开(公告)号：US11773150B2
公开(公告)日：2023-10-03
申请号：US17004395
申请日：2020-08-27
发明人： Paul E. Carrington , Grigori Ermakov , Robert M. Garbaccio , Wolfgang Seghezzi , Elisabetta Bianchi , Federica Orvieto , Dennis Gately , Nick Knudsen , Anthony Manibusan
CPC分类号： C07K14/605 , A61K47/6811 , A61K47/6843 , A61P3/10 , C07K16/26 , C07K16/2869 , A61K2039/505 , C07K2317/75 , C07K2319/00
摘要： Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
-
公开(公告)号：US20230099074A1
公开(公告)日：2023-03-30
申请号：US18049711
申请日：2022-10-26
发明人： Philip E. Brandish , Robert M. Garbaccio , Jeffrey Kern , Linda Liang , Sanjiv Shah , Dennis Zaller , Andrew Beck , Dennis Gately , Nick Knudsen , Anthony Manibusan , Jianing Wang , Ying Sun
摘要： Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.022 秒)
